The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC).
Jyoti D. Patel
No relevant relationships to disclose
Edward B. Garon
Research Funding - Lilly
Ramaswamy Govindan
Consultant or Advisory Role - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Honoraria - Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; Merck
Craig H. Reynolds
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - Lilly
David R. Spigel
Consultant or Advisory Role - Lilly
Mark R. Olsen
No relevant relationships to disclose
Robert C. Hermann
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Lilly; Roche
Jingyi Liu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Susan C. Guba
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Eduardo J. Pennella
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Coleman K. Obasaju
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Philip D. Bonomi
Consultant or Advisory Role - ImClone Systems; Lilly
Research Funding - ImClone Systems; Lilly
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly